Why Antitrust Keeps Losing to the Big Players — and the Map Courts Have Drawn to Win
A historical survey of competition enforcement in the veterinary industry, and the three-gate standing problem that has shielded the largest corporate players from the courthouse — supported by publicly available court filings.
There is a pattern in veterinary antitrust litigation that is easy to miss if you read the headlines and not the dockets. Complaints describe conduct that sounds plainly anticompetitive — long-term exclusive contracts, output restrictions, suppressed wages, supracompetitive prices. The defendants are some of the largest and most consolidated companies in the industry. And yet, case after case, the plaintiffs lose. Not on the facts. Not on a jury’s view of the conduct. They lose at the threshold, before any court ever weighs whether the conduct was actually unlawful.
The reason is a doctrine called antitrust standing, and it functions less like a single rule than like a series of gates. To reach the merits of a federal antitrust claim, a plaintiff has to pass through all of them. Most veterinary plaintiffs make it through one or two and are turned away at the next. The conduct is never adjudicated. The case simply ends.
This article does two things. First, it surveys the history of competition enforcement in the veterinary industry — what has been brought, by whom, and how it has fared. Second, and more usefully, it reads the losing cases for what they teach: the courts, in explaining why each plaintiff failed, have effectively drawn a map of what a winning plaintiff would have to plead. That map is the most valuable thing in the case law, and almost nobody has assembled it in one place.
A short history of veterinary antitrust enforcement
For most of the twentieth century there was essentially nothing to survey. The veterinary sector was structured around fragmented, sole-practitioner ownership — too unconcentrated to attract the attention of federal competition enforcers. No reported federal or Federal Trade Commission antitrust action against a U.S. veterinary clinic chain, diagnostics supplier, or animal-health pharmaceutical company appears for decades. Enforcement begins, in any meaningful sense, only in the last fifteen years, and it tracks the consolidation of the industry almost exactly.
The first significant intervention was the FTC’s investigation of the diagnostics market leader in point-of-care veterinary testing, which began around 2010 and produced a consent order finalized in early 2013. The theory was monopolization through exclusive dealing: the company had locked up the three national veterinary distributors, foreclosing rivals from the great majority of the distribution channel. The remedy barred concurrent exclusive agreements with all three distributors and capped future contract terms. The company entered the order while denying wrongdoing.
From there, enforcement broadened into two adjacent areas. Animal-health pharmaceutical mergers drew sustained FTC attention — a series of consent orders required the divestiture of at least one product line in every horizontal pharma deal of consequence. And the rollup of specialty and emergency veterinary clinics by a global conglomerate and by a private-equity acquirer produced multiple FTC consent orders within a five-year span, several of them requiring clinic divestitures and, in the case of the private-equity acquirer, unusual prior-approval and nationwide prior-notice obligations imposed after the agency concluded it was dealing with a serial acquirer.
Two features of that record matter for everything that follows. First, the diagnostics-plus-imaging-plus-clinic vertical was, in practice, accepted without structural remedies in imaging — the major reference-laboratory and point-of-care diagnostics transactions closed without imaging-asset divestitures. Second, criminal antitrust enforcement against veterinary firms is essentially absent; the Department of Justice’s Antitrust Division has brought no criminal cartel cases in the sector. Enforcement has been civil, merger-focused, and — in imaging and teleradiology specifically — nonexistent.
The history is not one of vigorous enforcement that occasionally fails. It is one of narrow, civil, merger-focused enforcement that has never reached the imaging and teleradiology layer at all.
The three cases that define the present
Three private antitrust cases are currently live, and together they show the standing problem from three different angles. The accounts below are drawn from the parties’ own court filings.
The diagnostics case: pet owners against a point-of-care supplier
In a putative class action filed in 2022 and now pending in the District of Maine, twenty-two named pet owners allege that the dominant supplier of point-of-care veterinary diagnostic products — analyzers, consumables, and single-use rapid test kits — maintained a monopoly through exclusive contracting. According to the complaint, after the 2013 FTC order disrupted the company’s distributor-level exclusivity, it shifted to six-year exclusive contracts directly with veterinary practices, carrying annual minimum-purchase requirements running from roughly $20,000 to $95,000 and scaled “disloyalty” penalties that the complaint says can exceed half a million dollars. The complaint alleges the company holds more than a 70% share and retains well over 90% of its customers year to year.
The procedural history is where the lesson lives. In an order dated January 8, 2024, the court dismissed the federal Sherman Act claims for lack of antitrust standing while declining, without prejudice, to dismiss the parallel state-law claims. A later ruling in 2025 narrowed the surviving state-law claims further but allowed a subset to proceed; the case remains pending. The pet owners’ federal theory — the one aimed squarely at the conduct — did not survive the threshold. The state-law claims did, and only because many states have repealed the federal indirect-purchaser bar.
The accreditation case: a veterinary school against a professional association
In a complaint filed in June 2025 in the Eastern District of Tennessee, a university that operates the largest veterinary-education program in the country by enrollment alleges that a national veterinary professional association, acting through its Council on Education, holds a monopoly over veterinary-school accreditation and has used newly emphasized research and teaching-hospital standards to restrict the entry and expansion of new schools. The complaint quotes the association’s own published statements expressing concern that additional veterinary graduates could create “downward economic pressure” — language the plaintiff characterizes as an admission of anticompetitive purpose. The association’s motion to dismiss runs the standard threshold defenses: the claims are not ripe, the plaintiff alleges harm to itself rather than to competition, any injury flows from state licensing laws rather than from the association, and accreditation conduct is shielded by state-action and petitioning immunities.
What makes this case notable is that the Department of Justice’s Antitrust Division filed a Statement of Interest in December 2025. The Department took no position on the merits but argued against the immunity defenses — contending that a private association promulgating and enforcing accreditation criteria is not exempt from the antitrust laws merely because states require practitioners to graduate from an accredited school, and that federal recognition of an accreditor does not bar antitrust scrutiny of its standards. It is the most assertive federal posture yet seen in a veterinary antitrust matter.
The labor case: veterinary trainees against the match system
In a class action pending in the Western District of Virginia, with a consolidated amended complaint filed in March 2026, two veterinarians who served as interns allege that the Veterinary Internship and Residency Matching Program operates as a wage-suppression cartel. The complaint names not only the match administrators but a wide set of corporate hospital chains and university veterinary schools, alleging that the match prohibits salary negotiation, channels roughly 90% of intern and residency positions through a binding allocation, exchanges compensation data among employers, and enforces compliance with multi-year bans. The relevant market is pleaded as a national labor market for veterinary intern and resident services, and the restraint is pleaded both as a per se violation and, in the alternative, under the rule of reason.
The labor case is the newest front, and it is significant for a reason beyond its own facts: the corporate hospital chains it names as defendants are the same consolidated operators that appear in the merger-enforcement history above. The conduct has simply surfaced on the labor side of the same companies.
Why antitrust fails: the three gates
Antitrust standing is not one question. It is a sequence of them, and a plaintiff has to clear every one to reach a merits ruling on a federal claim. The veterinary cases fail at different gates, which is precisely why the failures look scattered until you line them up.
The three standing gates. A federal antitrust plaintiff must pass all three before any court evaluates the conduct itself. Veterinary plaintiffs have repeatedly been turned away at one gate or another — which is why the conduct in these cases is so rarely adjudicated.
Gate one: antitrust injury and market participation
The first gate asks whether the plaintiff is the right kind of party. Drawing on the Supreme Court’s Associated General Contractors framework, courts ask whether the plaintiff is a consumer or competitor in the specific market alleged to be restrained, and whether the injury is of the type the antitrust laws exist to prevent. The diagnostics case is the clean illustration. The pet-owner plaintiffs paid more, the harm was real, and improper motive was effectively conceded — and the federal claims still failed. The court’s reasoning was that the restrained market was the market for diagnostic products, while the pet owners were participants in the market for veterinary services. They were one market removed from the restraint, and therefore not the presumptively proper plaintiffs. Some courts elsewhere allow an “inextricably intertwined” theory to bridge that gap; the First Circuit has specifically declined to treat that phrase as a test for standing.
Gate two: the indirect-purchaser bar
The second gate is the Illinois Brick rule. Under federal antitrust law, only a direct purchaser from the alleged violator may recover damages; a buyer further down the chain generally may not. Pet owners buy diagnostic products, when they buy them at all, through their veterinarians — two steps from the manufacturer. That is why the diagnostics case, and the broader pattern of pet-owner antitrust suits, collapses to state-law claims: a substantial number of states have enacted repealer statutes permitting indirect-purchaser damages under state law. It is worth noting what this gate does not bar. Courts have held the indirect-purchaser rule applies to damages, not to claims for injunctive relief — a distinction that turns out to matter a great deal for the roadmap below.
Gate three: harm to competition, and the immunity shields
The third gate asks whether the complaint pleads harm to competition itself rather than harm to the individual plaintiff, and whether it can survive the immunity defenses a sophisticated defendant will raise. The accreditation case sits squarely against this gate. The defense argues that the plaintiff pleads injury to itself while dozens of other veterinary schools continue to compete, so competition as a whole is unharmed; that any injury actually flows from state licensing laws rather than from the association’s conduct, breaking the causal chain; and that accreditation activity is shielded by state-action and petitioning immunities. Those immunity doctrines are not minor technicalities — they are the principal obstacle between the association and a trial on the merits, which is exactly why the Department of Justice intervened to argue against them.
The pattern in one sentence
A defendant with market power sits behind three gates: direct purchasers may have antitrust injury but are often bound by the very contracts at issue; indirect purchasers clear the market test only awkwardly and then hit the indirect-purchaser bar; competitors clear standing but run into “harm to a competitor is not harm to competition.” Each plaintiff type bounces off a different wall — and the conduct is never reached.
The map: what a winning plaintiff would have to plead
The same opinions that dismiss these cases also, read carefully, describe what would survive. Courts are explicit about why each plaintiff failed, and each explanation is a specification for a plaintiff who would not. Assembled, those specifications form a roadmap. It is a roadmap for litigants and enforcers thinking about how to frame a viable claim — not, it should be said, a compliance how-to for operators; nothing here tells a company how to restructure conduct to evade scrutiny, only how the courthouse door is configured.
| Step | What the courts require | Where it comes from |
|---|---|---|
| 1. Plead the plaintiff inside the restrained market | Define the antitrust market as the product or service the plaintiff actually buys, and bring the plaintiff who buys it. The diagnostics case failed because pet owners were participants in the services market, not the diagnostic-products market. A direct customer of the restrained product does not have that problem. | Antitrust-injury and market-participant analysis under the Associated General Contractors factors. |
| 2. Match the plaintiff to the remedy | The indirect-purchaser bar applies to federal damages, not to injunctive relief. An injunction-only federal claim, or a damages claim brought under a state repealer statute, are the channels that remain open to indirect purchasers. | The Illinois Brick rule and its injunctive-relief exception; state repealer statutes. |
| 3. Plead harm to the process, not the balance sheet | Plead market-wide effects: foreclosure share, output reduction, barriers to entry, retention and switching data. The diagnostics complaint’s foreclosure figures are the model; a complaint that leads with the plaintiff’s own losses is the vulnerability. | The “harm to competition, not a competitor” requirement. |
| 4. Defeat the immunity shields head-on | Anticipate and plead around state-action and petitioning immunity: a private association’s voluntary standard-setting is not state action merely because states rely on it, and federal recognition of an accreditor is not antitrust immunity. | The position advanced by the Department of Justice in its Statement of Interest. |
| 5. Choose the forum and the law deliberately | Venue, choice of state law, and the per se / rule-of-reason framing are load-bearing decisions. State antitrust and consumer-protection statutes have repeatedly proven the more durable vehicle when federal claims fall at gate one or gate two. | The survival of state-law claims after federal dismissal in the diagnostics case. |
The case law that keeps dismissing veterinary antitrust suits is, read the other way, a set of instructions for the suit that would not be dismissed.
What this means for teleradiology
No published antitrust action — federal, state, or private — has named a veterinary teleradiology provider. Teleradiology and imaging assets were not the subject of divestitures in the major veterinary diagnostics and clinic transactions. The segment sits, at present, in an enforcement vacuum.
That vacuum is often read as reassurance. The standing map suggests the opposite reading. Consider the corporate aggregator model in its general form: a dominant supplier offering bundled diagnostics-and-teleradiology services to veterinary practices under long-term contracts. If such a contract were ever challenged, the obvious plaintiff would be the veterinary practice that signed it. And a veterinary practice is, structurally, the plaintiff the map calls for. It is a direct purchaser of the bundled service — clearing the indirect-purchaser gate. It is a participant in the very market alleged to be restrained — clearing the market-participation gate. And a well-pleaded complaint could allege market-wide foreclosure — the share of practices locked into long-term bundled contracts, the switching costs, the retention rate — clearing the harm-to-competition gate.
In other words, the bundled diagnostics-plus-teleradiology contract is one of the rare fact patterns that could clear all three gates at once. The pre-2013 exclusive-dealing model that drew the original FTC diagnostics enforcement is the closest structural analog. The reason teleradiology has not been litigated is not that the corporate diagnostic bundlers’ contracting practices would necessarily survive antitrust scrutiny. It is that, so far, no plaintiff who fits the map has brought the case. That is an observation about who has sued — not a verdict on the conduct.
Whether any specific bundling arrangement is in fact unlawful is a separate and fact-dependent question. Exclusive dealing is unlawful only on a showing of market power and substantial foreclosure; a tying claim requires its own elements. The structural point here is narrower and more durable: the segment most analogous to the one piece of veterinary diagnostics that has been enforced is also the segment with the cleanest available plaintiff.
The international bellwether: the UK CMA investigation
One foreign development belongs in any honest survey, even though it carries no precedential weight in a U.S. court. The UK Competition and Markets Authority — broadly, the British counterpart to the FTC and the Antitrust Division combined — has a statutory power its U.S. equivalents largely lack: it can investigate an entire industry, rather than a single company or merger, and impose binding sector-wide remedies. It used that power on the veterinary sector.
The CMA concluded a multi-year statutory market investigation into veterinary services for household pets with a final report published on 24 March 2026 (the accompanying press release is dated the following day). It found that the structure of the industry had changed substantially over the prior decade, with large veterinary groups having come to own a majority — on the CMA’s account, around 60% — of UK first-opinion practices, and that a lack of consumer-facing information was producing weak competition and high prices. The legally binding remedy package, to be implemented through CMA Orders and regulator undertakings by 23 September 2026, includes mandatory standardized price lists, disclosure of large-group ownership, prescription-fee caps, and a price-comparison facility; smaller businesses are given additional time to comply. The CMA also urged the UK government to modernize the legislation governing veterinary businesses.
The significance for a U.S. and teleradiology audience is not legal but evidentiary. The CMA investigation is the first instance of a competition regulator examining the consolidated, corporatized veterinary sector as a whole and concluding that competition was not functioning. The U.S. enforcement vacuum in imaging and teleradiology is not evidence that the segment is competitively healthy. It is evidence that, in the United States, no one with standing has yet brought the case — and, unlike the CMA, U.S. enforcers have no general power to investigate the sector as a whole without one.
The Verdict
An enforcement gap is not a clean bill of health
The veterinary antitrust record is not a story of conduct that has been tested and cleared. It is a story of conduct that has rarely been reached, because the plaintiffs who brought the cases could not clear the standing gates. The diagnostics case lost its federal claims at gate one. The pet-owner pattern repeatedly fails at gate two. The accreditation case is being fought at gate three, with the Department of Justice arguing against the immunity shields.
For veterinary teleradiology, two things follow. The segment has never been litigated — and the segment is also where a plaintiff who fits the courts’ own map most plausibly exists, in the form of a veterinary practice that is a direct purchaser, in-market, and able to plead foreclosure. Whether any particular bundled arrangement violates the antitrust laws remains a conditional, fact-specific question that no court has answered. But the absence of a case is a fact about litigation history, not a finding on the merits. The map exists. The plaintiff is identifiable. What is missing is the suit.
Frequently asked questions
Why do antitrust cases against large veterinary companies so often fail?
In the reported cases, the failures have rarely turned on whether the conduct was harmful. They have turned on standing — the threshold question of whether a particular plaintiff is legally entitled to bring the claim at all. Courts have dismissed veterinary antitrust complaints because the plaintiff was not a participant in the specific market alleged to be restrained, because an indirect-purchaser rule barred federal damages, or because the plaintiff pleaded harm to itself rather than harm to competition. The merits were never reached.
What is antitrust standing and how is it different from regular standing?
Article III standing is a constitutional minimum: a real injury, traceable to the defendant, that a court can redress. Antitrust standing is an additional, prudential filter that federal courts apply on top of it. Drawing on the Supreme Court’s decision in Associated General Contractors, courts weigh factors including whether the plaintiff suffered an injury of the type the antitrust laws were meant to prevent and how directly the alleged restraint caused that injury. A plaintiff can satisfy Article III and still lack antitrust standing.
What is the Illinois Brick rule?
Illinois Brick is a 1977 Supreme Court rule that, under federal antitrust law, only direct purchasers from an alleged violator may recover damages. Indirect purchasers — buyers further down the distribution chain — generally cannot. Many states have passed repealer statutes that allow indirect-purchaser damages claims under state law, which is why veterinary antitrust cases brought by pet owners frequently survive only as state-law claims. The rule applies to damages; courts have held it does not bar claims for injunctive relief.
Has any veterinary teleradiology company faced antitrust enforcement?
Based on publicly available records, no — no federal enforcement action, no state action, and no private antitrust suit has named a veterinary teleradiology provider. Teleradiology was not the subject of any divestiture in the major veterinary diagnostics and clinic transactions reviewed by competition regulators. It remains an un-litigated segment of the sector.
What is the UK CMA veterinary investigation and does it affect U.S. companies?
The UK Competition and Markets Authority conducted a multi-year statutory market investigation into veterinary services for household pets, concluding with a final report on 24 March 2026 and a binding package of price-transparency and disclosure remedies. It has no direct legal effect in the United States and sets no U.S. precedent, because it operates under UK statute. Its significance for a U.S. audience is as a bellwether: it is the first time a competition regulator has examined the consolidated, corporatized veterinary sector as a whole and concluded competition was not working.
This article is a journalistic survey prepared for informational purposes and is supported by publicly available court filings and public records. It describes pending litigation whose procedural posture may change after publication; case status is stated as of the publication date. Nothing here is legal advice, and no statement should be read as a conclusion that any named company has violated the law. Antitrust liability is fact-specific and conditional. Readers evaluating a specific situation should consult qualified competition counsel.